$DOCS

Doximity Draws Its First Downgrade Days After Its Pop

Doximity (NYSE:DOCS) rose slightly premarket after Wells Fargo downgraded it to Underweight from Equal Weight and set an $18 price target. The stock had jumped 32.58% following its earnings report. Wells Fargo said the outlook is unchanged but risk reward is unfavorable until the AI narrative links to clearer growth. Shares trade near $27.

Original reporting
Published Aug 10, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Doximity Draws Its First Downgrade Days After Its Pop — source image
Decision brief

The 30-second read

$DOCSBearishMed
01

Why it matters

The Wells Fargo Underweight call with an $18 target introduces a clear downside reference point and emphasizes uncertainty around translating AI into measurable growth.

02

Market read

Traders may reassess near-term risk/reward after a post-earnings spike when a major bank cuts rating and lowers the target to the bottom of a wide range.

03

What to watch

The article notes survey work suggests wallet-share gains are largely in the past, but it does not quantify new customer acquisition or retention metrics that could still support estimates.

Relevance 7/10Novelty 6/10Timing: premarket today after the downgrade was issued

Background

Doximity shares surged 32.58% on its earnings report days earlier, and the stock is now trading near faster-growing peers after that run-up.

Company-level read

Ticker impact

$DOCSBearishMedium confidence
Context

Wells Fargo downgraded Doximity to Underweight from Equal Weight and set an $18 price target after the stock’s 32.58% earnings jump.

Expected impact

Bias toward continued underperformance or choppy trading until investors get more concrete AI-driven growth evidence.

Evidence & confidence

The article’s actionable new fact is the downgrade plus a specific lower target ($18) relative to the cited $27 level, with a thesis tied to uncertainty in AI monetization and timing of wallet-share gains.

Market effects

Highlights how sell-side is discounting AI narratives for healthcare IT platforms until they show estimateable growth inflections.

None indicated.

None indicated.

Counterpoint

The downgrade says the outlook is essentially unchanged, so the market may already be pricing the risk and could still reward any continued AI-related traction.

Key entities

  • Doximity

    Digital platform for U.S. medical professionals, subject of the downgrade and price-target change.

  • Wells Fargo

    Issued the downgrade to Underweight and set the $18 price target.

  • Stan Berenshteyn

    Provided the thesis that the AI upside is hard to translate into estimates and that wallet-share gains may be largely behind.

Related articles

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.

$DOCSMed

Doximity Stock Surges in Overnight Trading as Chief Executive Highlights High-Margin AI Tool

Doximity (DOCS) shares jumped in overnight trading after CEO Jeffrey Tangney said the company’s new AI search tool generates over 10 times the revenue versus its operating cost. The stock later closed up 33% on Friday. Doximity reported Q1 revenue of $156.6M and adjusted EBITDA of $74.8M, and raised full-year guidance to $671M-$681M. Wells Fargo later downgraded to underweight.

$DOCSMedAI 8/10

DOCS Q2 Deep Dive: AI Product Adoption Fuels Revenue Growth, Margins Face Investment Pressures

Doximity reported Q2 revenue of $156.6M, up 7.3% year over year and above analysts’ $151.3M estimate. Adjusted EBITDA was $74.77M versus $69.59M, but adjusted EPS was $0.29 versus $0.30. The company slightly lifted full-year revenue guidance to $676M midpoint, while EBITDA guidance of $319M trails estimates. Management cited AI product adoption and NOHARM study validation, alongside higher AI investment pressuring margins.

$NTAPMedAI 8/10

Stocks making the biggest moves midday: NetApp, Intel, Apple, Doximity, Verisk Analytics & more

Midday movers included MarineMax, up 46% on a deal to be sold to Blackstone Infrastructure’s Safe Harbor Marinas for $53/share ($1.5B). Varex Imaging rose 48% after Teledyne agreed to buy it for $18.90/share. NetApp gained 6% on a Morgan Stanley rating change. Verisk fell over 5% after a judge ordered its $2.35B AccuLynx acquisition to proceed. Intel dropped nearly 3% after announcing $15B stock offering; Apple fell 2% after a Jefferies downgrade.

$DOCSMed

Here’s Why Doximity Stock Is Flying Today

Doximity (DOCS) shares rose sharply after its fiscal Q1 results and CEO Jeff Tangney’s comments on AI opportunities. Revenues grew 7% YoY, but net income and adjusted EBITDA fell. The company cited record AI usage, a growing AI commercial pipeline, and increased client engagement, and boosted guidance, driving the move.